BiotechTube
Home/Pipeline/FT011 (asengeprast)

FT011 (asengeprast)

Systemic sclerosis (scleroderma)

Phase 2Active

Key Facts

Indication
Systemic sclerosis (scleroderma)
Phase
Phase 2
Status
Active
Company
Certa Therapeutics

About Certa Therapeutics

Australian precision‑medicine biotech targeting fibrosis through GPR68 inhibition.

View full company profile

Therapeutic Areas

FibrosisNephrology

Other Systemic sclerosis (scleroderma) Drugs

DrugCompanyPhase
P1PeptinovPhase 1/2